Business Standard

Alembic Pharma reports 52% growth in Q3 PAT; US generic biz falls flat

US generics business too posted a marginal increase during quarter; company launched two products in US market

Pharmaceuticals, drugs, pharma industry, medical, health, lab
Premium

BS Reporter Ahmedabad
Vadodara headquartered Alembic Pharmaceuticals Ltd reported a 52 per cent year on year (YoY) rise in net profit for the third quarter of the 2017-18 fiscal to Rs 1.3 billion riding on the back of a 14 per cent y-o-y growth in the India formulations business while the US generics business saw flat growth.
The company's consolidated net sales for the quarter stood at Rs 8.4 billion, up 8 per cent YoY, while the Ebitda margin came in at 22 per cent compared to 19 per cent in the same quarter last year.
Pranav Amin, managing director, Alembic Pharmaceuticals said that India

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 31 2018 | 5:14 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com